Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results

Nuvectra Corp (NVTR) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/13/2019 GN Nuvectra® maintient la prise en charge de ses patients actuels dotés de l'implant Algovita® alors que la société dépose volontairement une requête en vertu du chapitre 11
11/13/2019 GN Nuvectra® unterstützt weiterhin bestehende Patienten mit dem Algovita®-Implantat, während das Unternehmen freiwillig ein Verfahren gemäß Chapter 11 beantragt
11/13/2019 GN Nuvectra®???????11???????Algovita®?????????
11/13/2019 GN Nuvectra® ???? 11 ?????,????? Algovita® ???????
11/13/2019 GN Nuvectra® Terus Mendukung Para Pasien dengan Implan Algovita® Saat Perusahaan Tersebut dengan Sukarela Mengajukan Perlindungan Bab 11
11/13/2019 GN ??????11???????????????????Algovita® Implant?????????????
11/13/2019 GN Nuvectra®, ????? 11? ??? ???? ??? ??? ??, ?? Algovita® ?? ?? ?? ???? ????? ??? ??
11/13/2019 GN Nuvectra® Terus Menyokong Pesakit Semasa dengan Implan Algovita® sementara Syarikat Memfailkan Bab 11 secara Sukarela
11/13/2019 GN Nuvectra® continua a apoiar seus pacientes com o Implante Algovita® enquanto a empresa entra com pedido de recuperação judicial
11/13/2019 GN Nuvectra® continúa apoyando a los pacientes existentes con el implante Algovita®, mientras la Compañía presenta petición de reestructuración voluntaria bajo el Capítulo XI
11/13/2019 GN Nuvectra® ????????????????????????????????????????????????????????? Algovita® ??????????????????????????????????????????????????? 11
11/12/2019 GN Nuvectra® Continuing to Support Current Patients with the Algovita® Implant as Company Voluntarily Files for Chapter 11
09/20/2019 GN Nuvectra® Appoints Jennifer Kosharek as Chief Financial Officer
08/26/2019 GN Nuvectra® Exploring Strategic Options to Enhance Shareholder Value
07/17/2019 GN Nuvectra to Report Second Quarter 2019 Financial Results on July 31, 2019
06/12/2019 GN Nuvectra® to Participate in Two Upcoming Investor Conferences
06/11/2019 GN Nuvectra Files Regulatory Submission with FDA for Algovita® Full-Body MR-Conditional Approval
05/30/2019 GN Nuvectra Highlights Positive Preliminary Algovita® Clinical Data at the INS 14th Annual World Congress
05/16/2019 GN Nuvectra® Announces Departure of COO & CFO Walter Z. Berger
05/01/2019 GN Nuvectra® Reports First Quarter 2019 Financial Results
04/22/2019 GN Nuvectra to Report First Quarter 2019 Financial Results on May 1, 2019
04/17/2019 GN Recent Analysis Shows Nuvectra, Red Lion Hotels, Rave Restaurant Group, Aeglea BioTherapeutics, CPI Aerostructures, and Qumu Market Influences — Renewed Outlook, Key Drivers of Growth
03/25/2019 GN Nuvectra® Appoints Anthony P. Bihl, III as New Chairman of the Board
02/28/2019 GN Nuvectra® Reports Fourth Quarter and Full Year 2018 Financial Results
02/26/2019 GN Nuvectra® to Present at 39th Annual Cowen Healthcare Conference
02/21/2019 GN The Future Is Now; Med Tech That's Changing Lives
02/19/2019 GN Nuvectra to Report Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019
01/07/2019 GN Nuvectra® Announces Preliminary Unaudited Fourth Quarter and Full Year 2018 Revenue
01/02/2019 GN Nuvectra Announces Divesture of NeuroNexus Subsidiary
12/12/2018 GN Nuvectra Receives Full-Body MR-Conditional CE Mark Approval for Algovita®
12/06/2018 GN Nuvectra Completes 3,000 U.S. Algovita® SCS Implantations
12/03/2018 GN Nuvectra Receives FDA Head-Only MR-Conditional Approval for Algovita®
10/31/2018 GN Nuvectra® to Participate in Two Upcoming Investor Conferences
10/22/2018 GN Nuvectra® to Report Third Quarter 2018 Financial Results on October 29, 2018
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy